A look at blockbuster origins shows the role of external innovation, but more of these huge franchises are in the hands of their inventors than ever before.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
The Japanese drug maker has four more conjugates coming behind Enhertu, and plans to keep future successes to itself.
Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
A slim survival benefit puts Gilead’s hopes of label expansion for Trodelvy on hold.